Plain-English translation of NCT07322237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether empagliflozin, a medication originally developed for diabetes, can help improve heart function when combined with (a blood pressure and heart medication) in patients with liver cirrhosis. Some participants will receive the medication combination, while others will receive with a placebo pill. The study aims to see if this treatment can prevent serious liver complications and improve survival.
Many patients with advanced liver disease develop heart problems that don't respond well to standard treatments alone. Researchers believe this medication may offer an additional benefit by helping the heart pump more effectively and reducing dangerous complications from liver disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the new medication combination or with a placebo pill for one year. You'll take your daily medication at home and come to clinic visits for heart ultrasounds, blood tests, and check-ups to monitor how the treatment is working and watch for any side effects. The study is double-blind, meaning neither you nor your doctor will know which group you're in.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
India